Camurus (CAMX.ST) Stock Analysis & AI Equity Report
Camurus (CAMX.ST) overview
Camurus (CAMX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Camurus reported revenue of SEK 2,265m and operating profit of SEK 884m; the year-end share price was 616.00 SEK and market capitalisation was SEK 36,488m. Camurus is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Camurus's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-11. Data will be refreshed during report generation.
About Camurus
Camurus AB is a Swedish biopharmaceutical company that develops and commercializes long-acting medicines for severe and chronic diseases. Its portfolio is built around the proprietary FluidCrystal technology and includes products and candidates in opioid dependence, endocrine disorders, pain, cancer, and other specialty care areas, supported by in-house research and commercial operations in Europe, Australia, and the US.
Generate the Camurus report
Camurus is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Camurus and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.